December 22, 2014 10:04 AM ET

Biotechnology

Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that a...

34175 Ardenwood Boulevard

Suite 100

Fremont, CA 94555

United States

Founded in 2007

35 Employees

Phone:

510-745-1700

Fax:

510-745-0493

Key Executives for Ardelyx, Inc.

Chief Executive Officer
Age: 49
Total Annual Compensation: $416.3K
Co-Founder
Age: 59
Total Annual Compensation: $310.0K
Vice President of Drug Development
Age: 53
Total Annual Compensation: $277.5K
Compensation as of Fiscal Year 2013.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Appoints Jeremy S. Caldwell as Executive Vice President and Chief Scientific Officer

Ardelyx, Inc. announced the appointment of Jeremy S. Caldwell, Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Caldwell brings a wealth of experience in drug discovery and development at several major pharmaceutical companies and in the biotechnology industry as an entrepreneur, having most recently served as Entrepreneur-in-Residence at Third Rock Ventures.

Ardelyx, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Ardelyx, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total revenue was $7,598,000 compared to $6,593,000 a year ago. Income from operations was $81,000 compared to loss from operations of $886,000 a year ago. Income before provision for income taxes was $74,000 compared to loss before provision for income taxes of $899,000 a year ago. Net income and comprehensive income was $74,000 compared to net loss and comprehensive loss of $934,000 a year ago. The increase in net income was primarily driven by the increase in recognized licensing revenue related to milestone payments in accordance with the Company's agreement with AstraZeneca partially offset by expenses related to being a public company following the Company's June 2014 IPO and increased R&D expenses. Net income attributable to common stockholders - Diluted was $74,000 compared to loss attributable to common stockholders of $934,000 a year ago. For the nine months, the company's total revenue was $25,284,000 compared to $5,967,000 a year ago. Income from operations was $2,369,000 compared to loss from operations of $2,147,000 a year ago. Income before provision for income taxes was $757,000 compared to loss before provision for income taxes of $2,189,000 a year ago. Net income and comprehensive income was $757,000 compared to net loss and comprehensive loss of $2,295,000 a year ago.

Ardelyx, Inc. to Report Q3, 2014 Results on Nov 06, 2014

Ardelyx, Inc. announced that they will report Q3, 2014 results on Nov 06, 2014

Similar Private Companies By Industry

Company Name Region
IATRICa, Inc. United States
PathoGene, L.L.C. United States
SBH Sciences, Inc. United States
TVAX Animal Health, LLC United States
GenWay Biotech, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.